Characterisation of a new isolate of Mycobacterium shimoidei from Finland.
This report describes the first isolation of Mycobacterium shimoidei in Finland from a sputum specimen obtained from an elderly female patient. M. shimoidei, a potential lung pathogen, is difficult to identify by routine methods and only a few cases have been reported. The present study demonstrated that M. shimoidei has a characteristic pattern for fatty acids and alcohols in gas liquid chromatography. This chromatogram and the pattern of mycolic acids on thin-layer chromatography allow it to be distinguished routinely. The unique sequence of the 16S rRNA gene and the 16S-23S rDNA spacer region allows identification by molecular methods.
Koukila-Kähkölä
Pirkko
P
*Institute of Biotechnology, University of Helsinki, 00014 Helsinki, †Helsinki University Central Hospital, 00250 Helsinki, ‡United Laboratories Ltd, 00381 Helsinki, Finland, §Department of Vaccine, National Institute of Public Health, 0461 Oslo, Norway, ||Peijas Hospital, 01400 Vantaa and **Clinical Microbiology, Kuopio University Hospital, 70211 Kuopio, Finland.
Paulin
Lars
L
*Institute of Biotechnology, University of Helsinki, 00014 Helsinki, †Helsinki University Central Hospital, 00250 Helsinki, ‡United Laboratories Ltd, 00381 Helsinki, Finland, §Department of Vaccine, National Institute of Public Health, 0461 Oslo, Norway, ||Peijas Hospital, 01400 Vantaa and **Clinical Microbiology, Kuopio University Hospital, 70211 Kuopio, Finland.
Brander
Eljas
E
*Institute of Biotechnology, University of Helsinki, 00014 Helsinki, †Helsinki University Central Hospital, 00250 Helsinki, ‡United Laboratories Ltd, 00381 Helsinki, Finland, §Department of Vaccine, National Institute of Public Health, 0461 Oslo, Norway, ||Peijas Hospital, 01400 Vantaa and **Clinical Microbiology, Kuopio University Hospital, 70211 Kuopio, Finland.
Jantzen
Erik
E
*Institute of Biotechnology, University of Helsinki, 00014 Helsinki, †Helsinki University Central Hospital, 00250 Helsinki, ‡United Laboratories Ltd, 00381 Helsinki, Finland, §Department of Vaccine, National Institute of Public Health, 0461 Oslo, Norway, ||Peijas Hospital, 01400 Vantaa and **Clinical Microbiology, Kuopio University Hospital, 70211 Kuopio, Finland.
Eho-Remes
Mirja
M
*Institute of Biotechnology, University of Helsinki, 00014 Helsinki, †Helsinki University Central Hospital, 00250 Helsinki, ‡United Laboratories Ltd, 00381 Helsinki, Finland, §Department of Vaccine, National Institute of Public Health, 0461 Oslo, Norway, ||Peijas Hospital, 01400 Vantaa and **Clinical Microbiology, Kuopio University Hospital, 70211 Kuopio, Finland.
Katila
Marja-Leena
ML
*Institute of Biotechnology, University of Helsinki, 00014 Helsinki, †Helsinki University Central Hospital, 00250 Helsinki, ‡United Laboratories Ltd, 00381 Helsinki, Finland, §Department of Vaccine, National Institute of Public Health, 0461 Oslo, Norway, ||Peijas Hospital, 01400 Vantaa and **Clinical Microbiology, Kuopio University Hospital, 70211 Kuopio, Finland.
D000368:Aged; D001483:Base Sequence; D002849:Chromatography, Gas; D002855:Chromatography, Thin Layer; D004275:DNA, Ribosomal / Q000737:chemistry; D005227:Fatty Acids / Q000032:analysis; D005233:Fatty Alcohols / Q000032:analysis; D005260:Female; D005387:Finland; D006801:Humans; D008969:Molecular Sequence Data; D009161:Mycobacterium / Q000737:chemistry* / Q000145:classification / Q000235:genetics; D009164:Mycobacterium Infections / Q000382:microbiology* / Q000473:pathology; D009171:Mycolic Acids / Q000032:analysis; D012336:RNA, Ribosomal, 16S / Q000235:genetics; D017422:Sequence Analysis, DNA; D013183:Sputum / Q000382:microbiology
D004275:DNA, Ribosomal; D005227:Fatty Acids; D005233:Fatty Alcohols; D009171:Mycolic Acids; D012336:RNA, Ribosomal, 16S